Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Biomaven has discovered the answer, the word is out on Brigatinib:

http://www.siliconinvestor.com/readmsg.aspx?msgid=30676938

Brigatinib:

Several of the second-generation ALK inhibitors could potentially replace crizotinib as first-line therapy. In treatment-naïve patients, crizotinib showed an ORR of 74% compared with 72%, 94%, and 100% from ceritinib, alectinib, and brigatinib, respectively. The median PFS was 10.9 months for patients on crizotinib, 18.4 months for ceritinib, more than 29 months for alectinib, and the median PFS was not reached for patients on brigatinib.4,5,6 For patients who have already shown resistance to ALK in¬hibitors, the second-generation drugs showed ORRs of 56% for ceritinib, 50% for alectinib, and 69% for brigatinib. The median PFS for patients on ceritinib was 6.9 months, 8.9 months for alectinib, and 13.4 months for brigatinib. - See more at: http://www.targetedonc.com/publications/targeted-therapy-news/2016/july-2016/tkis-competing-for-frontline-therapy-in-alk-nsclc#sthash.Snr0ci2L.dpuf